Proteomics-driven progress in neurodegeneration research
Proteomics technologies have been widely used in the investigation of neurodegenerative and psychiatric disorders, and in particular in the detection of differences between healthy individuals and patients suffering from such diseases. Thus, brain and cerebrospinal fluid (CSF) samples from patients...
Gespeichert in:
| Veröffentlicht in: | Electrophoresis 2006-04, Vol.27 (8), p.1556-1573 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1573 |
|---|---|
| container_issue | 8 |
| container_start_page | 1556 |
| container_title | Electrophoresis |
| container_volume | 27 |
| creator | Fountoulakis, Michael Kossida, Sophia |
| description | Proteomics technologies have been widely used in the investigation of neurodegenerative and psychiatric disorders, and in particular in the detection of differences between healthy individuals and patients suffering from such diseases. Thus, brain and cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease, Down syndrome, Pick's disease, Parkinson's disease, schizophrenia, and other disorders as well as brain and CSF from animals serving as models of neurological disorders have been analyzed by proteomics. 2‐DE followed by MALDI‐TOF‐MS has been mainly applied as this proteomics approach provides the possibility of convenient quantification of protein levels and detection of post‐translational modifications. About 330 unique proteins with deranged levels and modifications have been detected by proteomics approaches to be related to neurodegeneration and psychiatric disorders. They are mainly involved in metabolism pathways, cytoskeleton formation, signal transduction, guidance, detoxification, transport, and conformational changes. In this article, we provide a summary of the major contributions of proteomics technologies in the study of neurodegenerative and psychiatric diseases, in particular, in the detection of changes in protein levels and modifications related to these disorders. |
| doi_str_mv | 10.1002/elps.200500738 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67868880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67868880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4218-42a1c5cc60196655d2d8493e89b8d1aed2c8e6dc6e9d349555b215c65e7060ab3</originalsourceid><addsrcrecordid>eNqFkM9PwjAYhhujEUSvHs1O3oZf27XrjoYomBDFX5Fb07UfOB0btqDy3zsCQW-eevie9-2bh5BTCl0KwC6wnIcuAxAAKVd7pE0FYzGTiu-TNtCUx6C4aJGjEN4AIMmS5JC0qBRC8ATaRI18vcB6VtgQO198YhXNfT31GEJUVFGFS187nGKF3iyKuoqaCxpvX4_JwcSUAU-2b4c8X1899Qbx8K5_07scxjZhVMUJM9QKayXQTDa_OuZUknFUWa4cNeiYVSidlZg5nmTNrJxRYaXAFCSYnHfI-aa3mfWxxLDQsyJYLEtTYb0MWqZKKqWgAbsb0Po6BI8TPffFzPiVpqDXrvTald65agJn2-ZlPkP3i2_lNEC2Ab6KElf_1Omr4ejxb3m8yRZhgd-7rPHvzWKeCv1y29dyPOiP-w-Zvuc_tWyFZw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67868880</pqid></control><display><type>article</type><title>Proteomics-driven progress in neurodegeneration research</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Fountoulakis, Michael ; Kossida, Sophia</creator><creatorcontrib>Fountoulakis, Michael ; Kossida, Sophia</creatorcontrib><description>Proteomics technologies have been widely used in the investigation of neurodegenerative and psychiatric disorders, and in particular in the detection of differences between healthy individuals and patients suffering from such diseases. Thus, brain and cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease, Down syndrome, Pick's disease, Parkinson's disease, schizophrenia, and other disorders as well as brain and CSF from animals serving as models of neurological disorders have been analyzed by proteomics. 2‐DE followed by MALDI‐TOF‐MS has been mainly applied as this proteomics approach provides the possibility of convenient quantification of protein levels and detection of post‐translational modifications. About 330 unique proteins with deranged levels and modifications have been detected by proteomics approaches to be related to neurodegeneration and psychiatric disorders. They are mainly involved in metabolism pathways, cytoskeleton formation, signal transduction, guidance, detoxification, transport, and conformational changes. In this article, we provide a summary of the major contributions of proteomics technologies in the study of neurodegenerative and psychiatric diseases, in particular, in the detection of changes in protein levels and modifications related to these disorders.</description><identifier>ISSN: 0173-0835</identifier><identifier>EISSN: 1522-2683</identifier><identifier>DOI: 10.1002/elps.200500738</identifier><identifier>PMID: 16555340</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Alzheimer's disease ; Animals ; Antioxidants - analysis ; Apoptosis ; Brain ; Brain Chemistry ; Central Nervous System Diseases - metabolism ; Cerebrospinal fluid ; Disease Models, Animal ; Down syndrome ; Energy Metabolism ; Fetus ; Heat-Shock Proteins - analysis ; Humans ; Mental Disorders - metabolism ; Neurodegenerative Diseases - metabolism ; Neuroproteomics ; Proteomics ; Signal Transduction</subject><ispartof>Electrophoresis, 2006-04, Vol.27 (8), p.1556-1573</ispartof><rights>Copyright © 2006 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4218-42a1c5cc60196655d2d8493e89b8d1aed2c8e6dc6e9d349555b215c65e7060ab3</citedby><cites>FETCH-LOGICAL-c4218-42a1c5cc60196655d2d8493e89b8d1aed2c8e6dc6e9d349555b215c65e7060ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Felps.200500738$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Felps.200500738$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16555340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fountoulakis, Michael</creatorcontrib><creatorcontrib>Kossida, Sophia</creatorcontrib><title>Proteomics-driven progress in neurodegeneration research</title><title>Electrophoresis</title><addtitle>ELECTROPHORESIS</addtitle><description>Proteomics technologies have been widely used in the investigation of neurodegenerative and psychiatric disorders, and in particular in the detection of differences between healthy individuals and patients suffering from such diseases. Thus, brain and cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease, Down syndrome, Pick's disease, Parkinson's disease, schizophrenia, and other disorders as well as brain and CSF from animals serving as models of neurological disorders have been analyzed by proteomics. 2‐DE followed by MALDI‐TOF‐MS has been mainly applied as this proteomics approach provides the possibility of convenient quantification of protein levels and detection of post‐translational modifications. About 330 unique proteins with deranged levels and modifications have been detected by proteomics approaches to be related to neurodegeneration and psychiatric disorders. They are mainly involved in metabolism pathways, cytoskeleton formation, signal transduction, guidance, detoxification, transport, and conformational changes. In this article, we provide a summary of the major contributions of proteomics technologies in the study of neurodegenerative and psychiatric diseases, in particular, in the detection of changes in protein levels and modifications related to these disorders.</description><subject>Alzheimer's disease</subject><subject>Animals</subject><subject>Antioxidants - analysis</subject><subject>Apoptosis</subject><subject>Brain</subject><subject>Brain Chemistry</subject><subject>Central Nervous System Diseases - metabolism</subject><subject>Cerebrospinal fluid</subject><subject>Disease Models, Animal</subject><subject>Down syndrome</subject><subject>Energy Metabolism</subject><subject>Fetus</subject><subject>Heat-Shock Proteins - analysis</subject><subject>Humans</subject><subject>Mental Disorders - metabolism</subject><subject>Neurodegenerative Diseases - metabolism</subject><subject>Neuroproteomics</subject><subject>Proteomics</subject><subject>Signal Transduction</subject><issn>0173-0835</issn><issn>1522-2683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9PwjAYhhujEUSvHs1O3oZf27XrjoYomBDFX5Fb07UfOB0btqDy3zsCQW-eevie9-2bh5BTCl0KwC6wnIcuAxAAKVd7pE0FYzGTiu-TNtCUx6C4aJGjEN4AIMmS5JC0qBRC8ATaRI18vcB6VtgQO198YhXNfT31GEJUVFGFS187nGKF3iyKuoqaCxpvX4_JwcSUAU-2b4c8X1899Qbx8K5_07scxjZhVMUJM9QKayXQTDa_OuZUknFUWa4cNeiYVSidlZg5nmTNrJxRYaXAFCSYnHfI-aa3mfWxxLDQsyJYLEtTYb0MWqZKKqWgAbsb0Po6BI8TPffFzPiVpqDXrvTald65agJn2-ZlPkP3i2_lNEC2Ab6KElf_1Omr4ejxb3m8yRZhgd-7rPHvzWKeCv1y29dyPOiP-w-Zvuc_tWyFZw</recordid><startdate>20060401</startdate><enddate>20060401</enddate><creator>Fountoulakis, Michael</creator><creator>Kossida, Sophia</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060401</creationdate><title>Proteomics-driven progress in neurodegeneration research</title><author>Fountoulakis, Michael ; Kossida, Sophia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4218-42a1c5cc60196655d2d8493e89b8d1aed2c8e6dc6e9d349555b215c65e7060ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Alzheimer's disease</topic><topic>Animals</topic><topic>Antioxidants - analysis</topic><topic>Apoptosis</topic><topic>Brain</topic><topic>Brain Chemistry</topic><topic>Central Nervous System Diseases - metabolism</topic><topic>Cerebrospinal fluid</topic><topic>Disease Models, Animal</topic><topic>Down syndrome</topic><topic>Energy Metabolism</topic><topic>Fetus</topic><topic>Heat-Shock Proteins - analysis</topic><topic>Humans</topic><topic>Mental Disorders - metabolism</topic><topic>Neurodegenerative Diseases - metabolism</topic><topic>Neuroproteomics</topic><topic>Proteomics</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fountoulakis, Michael</creatorcontrib><creatorcontrib>Kossida, Sophia</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Electrophoresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fountoulakis, Michael</au><au>Kossida, Sophia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proteomics-driven progress in neurodegeneration research</atitle><jtitle>Electrophoresis</jtitle><addtitle>ELECTROPHORESIS</addtitle><date>2006-04-01</date><risdate>2006</risdate><volume>27</volume><issue>8</issue><spage>1556</spage><epage>1573</epage><pages>1556-1573</pages><issn>0173-0835</issn><eissn>1522-2683</eissn><abstract>Proteomics technologies have been widely used in the investigation of neurodegenerative and psychiatric disorders, and in particular in the detection of differences between healthy individuals and patients suffering from such diseases. Thus, brain and cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease, Down syndrome, Pick's disease, Parkinson's disease, schizophrenia, and other disorders as well as brain and CSF from animals serving as models of neurological disorders have been analyzed by proteomics. 2‐DE followed by MALDI‐TOF‐MS has been mainly applied as this proteomics approach provides the possibility of convenient quantification of protein levels and detection of post‐translational modifications. About 330 unique proteins with deranged levels and modifications have been detected by proteomics approaches to be related to neurodegeneration and psychiatric disorders. They are mainly involved in metabolism pathways, cytoskeleton formation, signal transduction, guidance, detoxification, transport, and conformational changes. In this article, we provide a summary of the major contributions of proteomics technologies in the study of neurodegenerative and psychiatric diseases, in particular, in the detection of changes in protein levels and modifications related to these disorders.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>16555340</pmid><doi>10.1002/elps.200500738</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0173-0835 |
| ispartof | Electrophoresis, 2006-04, Vol.27 (8), p.1556-1573 |
| issn | 0173-0835 1522-2683 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67868880 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Alzheimer's disease Animals Antioxidants - analysis Apoptosis Brain Brain Chemistry Central Nervous System Diseases - metabolism Cerebrospinal fluid Disease Models, Animal Down syndrome Energy Metabolism Fetus Heat-Shock Proteins - analysis Humans Mental Disorders - metabolism Neurodegenerative Diseases - metabolism Neuroproteomics Proteomics Signal Transduction |
| title | Proteomics-driven progress in neurodegeneration research |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A13%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proteomics-driven%20progress%20in%20neurodegeneration%20research&rft.jtitle=Electrophoresis&rft.au=Fountoulakis,%20Michael&rft.date=2006-04-01&rft.volume=27&rft.issue=8&rft.spage=1556&rft.epage=1573&rft.pages=1556-1573&rft.issn=0173-0835&rft.eissn=1522-2683&rft_id=info:doi/10.1002/elps.200500738&rft_dat=%3Cproquest_cross%3E67868880%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67868880&rft_id=info:pmid/16555340&rfr_iscdi=true |